SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff has centered on concerns about its debt burden, distressed bond trading, and ability to finance its AI data-center expansion. Goldman Sachs Buy upgrade prompted hopes for a rebound, but traders debated whether the move could overcome financing risks, with bearish concerns about dilution or default competing with dip-buying and oversold-bounce calls.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention for its steep slide to fresh lows, as traders question the companys business prospects and debate whether Trumps political standing and the approaching midterms could further weaken its appeal. Sentiment is heavily bearish, though a few traders see the decline as a buying opportunity or cite possible merger and fusion developments.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs continued slide to fresh lows is being tied to soft residential roofing demand, housing-sector pressure and analyst target cuts, with traders also pointing to high rates and suspected dilution. Many are frustrated by the decline and managements limited communication, while some long-term holders remain optimistic about the building-products roll-up and future integration gains.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

CBRS is drawing attention amid a steep post-IPO selloff, with traders pointing to IPO lockup share releases and reported insider selling as potential sources of pressure, alongside concerns about valuation, growth, and reliance on OpenAI. Bears expect further downside, while some bulls view the decline as overdone and are averaging in.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is drawing attention for its steep selloff and persistent underperformance, with traders citing weakness in crypto and AI infrastructure alongside concern about its CoreWeave tenancy and delays in securing additional data-center tenants. Many blame management and a lack of communication, while some remain hopeful that Helios revenue or earnings will demonstrate the businesss potential.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood shares are under pressure amid a sustained selloff, with analyst caution and valuation concerns ahead of earnings adding to traders worries; some also point to broader market weakness and crypto declines. The bearish mood and speculation about insider selling or unusual activity contrast with dip-buyers who see the decline as an opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of CorMedixs REZZAYO supplemental application for priority review in invasive fungal-disease prevention is drawing attention, with traders focused on the potential label expansion and upcoming regulatory decision. Enthusiasm is tempered by frustration that the news has barely moved the share price and broader concerns about DefenCaths reimbursement and competition; acceptance does not guarantee approval.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after its Phase 3 APOLLO trial of bitopertin met both primary and all secondary endpoints in erythropoietic protoporphyria, strengthening the case for an FDA resubmission after an earlier rejection. Traders are weighing the positive results and potential short-covering against profit-taking, heavy selling, and the remaining regulatory uncertainty.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoin and broader crypto-market volatility are driving attention, with traders repeatedly criticizing COIN for falling sharply on weak crypto days while lagging during rebounds. Sentiment is split between frustration over its underperformance and hopes for a recovery, with upcoming quarterly results adding to the debate.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs better-than-guided third-quarter results and upbeat outlook for higher EBITDA have driven a sharp rally, with traders also discussing potential short covering. Bulls see improving steel pricing and contracts supporting a recovery, while skeptics question whether the outlook can overcome the companys debt and past volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Equity

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication 

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer

MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen Corp.

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock surged more than 177% at close after it said that its experimental drugs, Zenkuda and KSI-501, had met the primary endpoints in its Phase 3 Daybreak trial.</li><li>RGEN stock gained more than 2% at close, extending gains amid positive investor sentiment following its strong second-quarter 2026 earnings beat, increased full-year financial guidance, and expansion into cell therapy.</li><li>BIIB stock gained about 0.5% at close on Monday amid a buy-in following its strong second-quarter 2026 earnings, recent strategic acquisitions, and positive product pipeline updates.&nbsp;</li></ul>Shares of pharmaceutical companies Kodiak Sciences Inc. (<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>), Repligen Corp. (RGEN) and Biogen Inc. (BIIB) surged to fresh 52-week highs on Monday amid positive trial results and strong earnings reports.&nbsp;<a href="https://stocktwits.com/symbol/KOD">KOD stock</a> surged more than 177% at close after it said that its experimental drugs, Zenkuda and KSI-501, had met the primary endpoints in its Phase 3 Daybreak trial.<a href="https://stocktwits.com/symbol/RGEN">RGEN stock</a> gained more than 2% at close, extending gains amid positive investor sentiment following its strong second-quarter 2026 earnings beat, increased full-year financial guidance, and expansion into cell therapy.<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> gained about 0.5% at close on Monday amid a buy-in following its strong second-quarter 2026 earnings, recent strategic acquisitions, and positive product pipeline updates.&nbsp;<h2 class="st-heading-2">Kodiak Sciences Makes It To September’s Top Five Biotech Gainers</h2><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock jumped to a 52-week high of $95.77 on Monday, its steepest climb on record, after the company scored a major drug win.&nbsp;Kodiak&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kod-stock-september-top-5-biotech-gainers-eye-drug-shkreli-still-sucks/cZMmZ2VRBXj">said</a> Monday that its two experimental therapies, Zenkuda and KSI-501, met the primary endpoints in the Phase 3 Daybreak trial, with both delivering vision improvements that were non-inferior to those seen with 2-mg aflibercept, the active ingredient in Regeneron’s original Eylea.&nbsp;The company reported no cases of intraocular inflammation in the Zenkuda arm and plans to seek regulatory approval in the fourth quarter, supported by positive data from five Phase 3 studies spanning three eye diseases.&nbsp;KSI-501, also known as Tabirafusp-ted, uses a different mechanism, and Kodiak plans additional analyses to determine whether certain wet AMD patients could benefit from its IL-6-targeting component. A separate Phase 3 study is evaluating KSI-501 in diabetic macular edema.On Stocktwits, retail sentiment around <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock was ‘extremely bullish’ at the time of writing. The company's shares have rallied more than 245% in 2026.&nbsp;<h2 class="st-heading-2">Repligen Extends Gains From Strong Quarter 2026&nbsp;</h2>RGEN stock climbed to a 52-week high of $198.87 on Monday, putting it on track for a sixth straight month of gains amid strong earnings, higher full-year guidance, and a major expansion into cell therapy.The company reported Q2 revenue of $204.1 million, up about 12% year over year, while adjusted earnings per share of $0.54 exceeded analyst expectations. Management subsequently raised its 2026 organic revenue-growth outlook to 10.5%-13.5% and increased adjusted EPS guidance to $2.03-$2.09.&nbsp;Repligen also recently agreed to acquire BioLife Solutions for approximately $1.5 billion, expanding its portfolio into cell-therapy biopreservation and strengthening its position in the growing cell and gene therapy market. The transaction is expected to broaden Repligen’s addressable market and add complementary products and capabilities.&nbsp;On Stocktwits, retail sentiment around RGEN stock was ‘bullish’ at the time of writing. The company's shares are up more than 18% this year.&nbsp;<h2 class="st-heading-2">Biogen Rises On The Back Of Strong Earnings, Positive Product Pipeline Updates</h2>BIIB stock rose to an annual high of $230.49 on Monday, putting it on track for a second consecutive month of gains as investors responded to strong second-quarter 2026 results, accelerating growth across its newer products and a series of pipeline and strategic developments.&nbsp;The company’s growth portfolio generated $1.06 billion in Q2 revenue, up 24% year-over-year, driven by continued launches and sales momentum for Skyclarys, Qalsody, Zurzuvae and Leqembi.Biogen also reported several pipeline catalysts. Leqembi received approval in Japan for a more convenient pen-based, at-home administration and a new formulation, Leqembi Iqlik.&nbsp;The company agreed to acquire RayThera for about $1 billion, strengthening its immunology portfolio, while Salanersen received FDA Breakthrough Therapy designation for spinal muscular atrophy.&nbsp;Biogen also highlighted encouraging clinical data for Zorevunersen in Dravet syndrome.On Stocktwits, retail sentiment around BIIB stock was ‘neutral’ at the time of writing. The company's shares have gained more than 28% in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kodiak Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biogen Inc

Kodiak Sciences Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$175.48
Prev Close	$175.42
Open	$178.47
Dividend Yield	0.00%
50-Day Moving Average	$175.78
Beta	1.42
Avg. Volume	1.07M
PE Ratio	239.09

52-Week High	$198.87
52-Week Low	$100.99
Market Capitalization	$11.14B
EPS (Annual)	$0.8644
Price to Book	4.69
Revenue Per Employee	$369,128.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

RGEN Fundamentals